Cargando…

Virtual screening FDA approved drugs against multiple targets of SARS‐CoV‐2

The outbreak of the novel coronavirus severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2), the causative agent of coronavirus disease 2019 (COVID‐19) respiratory disease, led to a global pandemic with high morbidity and mortality. Despite frenzied efforts in therapeutic development, there a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Hualou, Zhao, Liang, Gong, Xiajing, Hu, Meng, Wang, Hongbin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014887/ https://www.ncbi.nlm.nih.gov/pubmed/33606912 http://dx.doi.org/10.1111/cts.13007

Ejemplares similares

Computational Insights and Virtual Screening of Repurposed FDA-Approved Drug Against SARS-CoV-2 Protease
por: Joel, C., et al.
Publicado: (2023)

Information Extraction From FDA Drug Labeling to Enhance Product-Specific Guidance Assessment Using Natural Language Processing
por: Shi, Yiwen, et al.
Publicado: (2021)

Screening of FDA Approved Drugs Against SARS-CoV-2 Main Protease: Coronavirus Disease
por: Balakrishnan, Vijayakumar, et al.
Publicado: (2020)

Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An in silico study
por: Akinlalu, Alfred Olaoluwa, et al.
Publicado: (2021)

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020)

Binary-QSAR guided virtual screening of FDA approved drugs and compounds in clinical investigation against SARS-CoV-2 main protease
por: OKTAY, Lalehan, et al.
Publicado: (2021)

Identification of FDA-approved drugs against SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) through computational virtual screening
por: Jade, Dhananjay, et al.
Publicado: (2022)

Virtual Screening of FDA-Approved Drugs against LasR of Pseudomonas aeruginosa for Antibiofilm Potential
por: Sadiq, Suhaib, et al.
Publicado: (2020)

Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2
por: Ku, Keun Bon, et al.
Publicado: (2020)

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
por: Jeon, Sangeun, et al.
Publicado: (2020)

Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets
por: Park, Su-Jin, et al.
Publicado: (2020)

Virtual Screening of FDA-Approved Drugs for Enhanced Binding with Mitochondrial Aldehyde Dehydrogenase
por: Zhou, Boqian, et al.
Publicado: (2022)

Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2
por: Peele, K.Abraham, et al.
Publicado: (2021)

Screening of an FDA-Approved Library for Novel Drugs against Y. pestis
por: Gur, David, et al.
Publicado: (2021)

Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs
por: Gu, Shuo, et al.
Publicado: (2018)

Virtual Screening for FDA-Approved Drugs That Selectively Inhibit Arginase Type 1 and 2
por: Detroja, Trishna Saha, et al.
Publicado: (2022)

Fully automated virtual screening pipeline of FDA-approved drugs using Caver Web
por: Musil, Milos, et al.
Publicado: (2022)

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
por: Caly, Leon, et al.
Publicado: (2020)

Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2
por: Dittmar, Mark, et al.
Publicado: (2021)

Identification of FDA Approved Antiviral Drugs for COVID-19 Treatment using Unbiased Virtual Screening
por: Greer, Rory, et al.
Publicado: (2021)

Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods
por: Ginex, Tiziana, et al.
Publicado: (2021)

Computational models identify several FDA approved or experimental drugs as putative agents against SARS-CoV-2
por: Bobrowski, Tesia, et al.
Publicado: (2020)

FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy
por: Drożdżal, Sylwester, et al.
Publicado: (2020)

Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine
por: Plaze, Marion, et al.
Publicado: (2021)

Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro
por: Xiong, Hua-Long, et al.
Publicado: (2021)

Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen
por: Taha, Zaid, et al.
Publicado: (2022)

Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, and in vitro Studies
por: Kulandaisamy, Rajkumar, et al.
Publicado: (2022)

Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors
por: Jiménez-Alberto, Alicia, et al.
Publicado: (2020)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Virtual screening and drug repositioning of FDA-approved drugs from the ZINC database to identify the potential hTERT inhibitors
por: Afzaal, Hasan, et al.
Publicado: (2022)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction
por: Fu, Wenyu, et al.
Publicado: (2020)

FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms
por: Ahmed, Mahmoud S., et al.
Publicado: (2023)

Screening of FDA-Approved Drugs for Inhibitors of Japanese Encephalitis Virus Infection
por: Wang, Shaobo, et al.
Publicado: (2017)

Screening of antibacterial compounds with novel structure from the FDA approved drugs using machine learning methods
por: Li, Wen-Xing, et al.
Publicado: (2022)

Mitoxantrone dihydrochloride, an FDA approved drug, binds with SARS-CoV-2 NSP1 C-terminal
por: Kumar, Prateek, et al.
Publicado: (2022)

Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL(pro) through high-throughput virtual screening and molecular dynamics simulation
por: Liu, Wen-Shan, et al.
Publicado: (2021)

In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication
por: Touret, Franck, et al.
Publicado: (2020)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_batt5t92m3m0fl64pupn80118h